Blurbs

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Syndax Pharmaceuticals (SNDX) and Apellis Pharmaceuticals (APLS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enanta Pharmaceuticals (Research Report) with bullish sentiments.

Enanta Pharmaceuticals (ENTA)

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Enanta Pharmaceuticals on August 9 and set a price target of $90.00. The company’s shares closed last Wednesday at $67.89.

According to -4.6% and a 46.1% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and VistaGen Therapeutics.

Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $75.78, a 10.8% upside from current levels. In a report issued on July 29, Piper Sandler also maintained a Buy rating on the stock with a $87.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Syndax Pharmaceuticals (SNDX)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Syndax Pharmaceuticals on August 8 and set a price target of $32.00. The company’s shares closed last Wednesday at $24.00, close to its 52-week high of $25.71.

According to 5.7% and a 51.0% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Syndax Pharmaceuticals is a Strong Buy with an average price target of $32.25, implying a 32.5% upside from current levels. In a report issued on July 28, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $31.00 price target.

Apellis Pharmaceuticals (APLS)

Robert W. Baird analyst Colleen M. Kusy reiterated a Buy rating on Apellis Pharmaceuticals on August 8 and set a price target of $90.00. The company’s shares closed last Wednesday at $66.44, close to its 52-week high of $67.74.

According to -33.1% and a 17.1% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Karyopharm Therapeutics, and Harpoon Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $76.17 average price target, a 17.7% upside from current levels. In a report issued on August 9, Needham also maintained a Buy rating on the stock with a $70.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ENTA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos